AI-generated summary
This scoping review of 2020 to 2025 literature examined platelet-rich plasma, photobiomodulation, stem cells, and exosomes for androgenetic alopecia. The authors report that platelet-rich plasma is the most studied option, but recent studies have inconsistent reporting and short follow-up. They describe photobiomodulation efficacy as debated, and stem cells and exosomes as promising but limited in clinical evidence.
- Who or what was studied
- Adults with androgenetic alopecia
- Limits stated in the abstract
- The abstract notes inconsistent reporting of cellular composition and device parameters, short follow-up durations, lack of comparative data, and limited clinical evidence for stem cells and exosomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Regenerative therapies have emerged in recent years. In particular, their utility in managing androgenetic alopecia-the most prevalent hair loss condition worldwide, affecting up to half of adults-is an active area of research. Navigating this space can be challenging for physicians due to widespread commercialization, lack of high-quality evidence, and an evolving regulatory landscape.
Objective
To critically review recently published evidence (2020-2025) on platelet-rich plasma, photobiomodulation, stem cells, and exosomes for the treatment of androgenetic alopecia.
Methods
A scoping review was conducted using PubMed, Embase (Ovid) and the Cochrane Controlled Register of Trials in February and November of 2025. Combination therapies were excluded.
Results And Conclusions
Platelet-rich plasma is the most studied modality, with emerging investigations into newer formulations such as leukocyte-rich and pure platelet-rich plasma. However, recent studies are limited by inconsistent reporting of cellular composition, short follow-up durations, and a lack of comparative data on treatment protocols. The efficacy of photobiomodulation as a monotherapy remains debated, with inconsistent reporting of device parameters. Stem cells and exosomes show promising, though still limited, clinical evidence in inducing hair regrowth. Standardization of these therapies is crucial, with emphasis on transparency, reproducibility, and patient safety.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Androgenetic alopecia, Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.